This study evaluated the clinical utility of nimotuzumab , a monoclonal anti-EGFR antibody , used concurrently with radiotherapy ( RT ) and chemoradiotherapy ( CRT ) in squamous cell carcinoma of the head and neck ( SCCHN ) .